Surmodics to Webcast Third Quarter Fiscal 2019 Earnings Conference Call on July 31

Webcast is Live at 4 p.m. (CT)

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2019 conference call on Wednesday, July 31, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon.

Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and chief financial officer, will recap the third quarter fiscal 2019 financial results and accomplishments. To access the webcast, go to the investor relations portion of the Company’s website at https://surmodics.gcs-web.com the day of the conference call and click on the webcast icon.

An audio replay will be available beginning at 7 p.m. CT on Wednesday, July 31, until 7 p.m. CT on Wednesday, August 7, and can be accessed by dialing 888-203-1112 and entering conference call ID passcode 6653187. In addition, the conference call audio and transcript will be archived on the Company’s website following the call.

About Surmodics, Inc.

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address unmet clinical needs for its medical device customers and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the SEC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190723005129/en/

Tim Arens
952-500-7000
[email protected]

Source: Surmodics, Inc.

You May Also Be Interested In

• BayCom Corp (BCML) Misses Q1 EPS by 4c
• Soligenix, Inc. (SNGX) Prices $4.75 Million Public Offering
• Pros Holdings (PRO) Appoints Todd McNabb as Chief Revenue Officer